questionText: To ask the Secretary of State for Health and Social Care, what steps her Department is taking to assess the potential (a) costs and (b) impact on patients of the use of (i) lecanemab , (ii) donanemab and (ii) other Alzheimer's drugs.
answerText: The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service on whether licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and ...
heading: Alzheimer's Disease: Drugs